Back to Journals » Patient Preference and Adherence » Volume 1

Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients

Authors Jörg Czekalla, Thomas Wagner, Alexander Schacht, Michael Kluge, Bruce Kinon

Published 20 December 2007 Volume 2007:1 Pages 19—27

DOI https://doi.org/10.2147/PPA.S2300

Jörg Czekalla1, Thomas Wagner2, Alexander Schacht2, Michael Kluge3, Bruce Kinon4

1Department of Psychiatry and Psychotherapy, RWTH Aachen University, Germany; 2Medical Department, Lilly Deutschland GmbH, Bad Homburg, Germany; 3Max Planck Institute for Clinical Psychiatry, Munich, Germany; 4Lilly Research Laboratories, Indianapolis, USA

Background: This study compared effectiveness and acceptance of orally disintegrating olanzapine tablets (ODT) with standard-coated tablets (SOT) in acutely ill psychiatric patients admitted to psychiatric hospitals for emergency treatment.

Methods: Large, prospective, observational study at hospital emergency units across Germany in patients with a diagnosis or tentative diagnosis of acute schizophrenia treated with ODT or SOT. Clinical (CGI-S and CGI-I) outcomes, attitudes towards medication (Nursing Assessment of Medication Acceptance, NAMA) scale, suicidal ideation, and adverse events were assessed at start of treatment and after 2 weeks.

Results: Both olanzapine formulations, ODT (N = 247) and SOT (N = 207), showed similar effectiveness after 2 weeks. CGI-I improved in 92.1% of patients (ODT: 91.8%, SOT: 92.3%). In patients receiving both formulations suicidal ideations were reduced (ODT from 53.9% to 20.6%, SOT from 51.2% to 22.7%). ODT was preferably given to severely ill (SOT: 49.8%, ODT: 64.4%) and aggressive patients. Adverse events were reported for 6.5% of ODT- and 2.9% of SOT-patients. This difference was possibly caused by the characteristics of patients receiving ODT.

Conclusions: This non-randomized, observational study shows comparable outcomes and tolerability in patients treated with both olanzapine formulations. In an acute treatment setting, orally disintegrating tablets were preferably used for more severely ill and aggressive patients with low medication acceptance.

Keywords: olanzapine, acute treatment, schizophrenia, observational study

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures

Murugan K, Choonara YE, Kumar P, Bijukumar D, du Toit LC, Pillay V

International Journal of Nanomedicine 2015, 10:2191-2206

Published Date: 18 March 2015

Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010

Bramlage P, Deutsch C, Krüger R, Wolf A, Müller P, Zwingers T, Beime B, Mengden T

Vascular Health and Risk Management 2014, 10:303-309

Published Date: 13 May 2014

The impact of PEGylation patterns on the in vivo biodistribution of mixed shell micelles

Gao H, Liu J, Yang C, Cheng T, Chu L, Xu H, Meng A, Fan S, Shi L, Liu J

International Journal of Nanomedicine 2013, 8:4229-4246

Published Date: 5 November 2013

Release profile and stability evaluation of optimized chitosan/alginate nanoparticles as EGFR antisense vector

Ebrahim Azizi, Alireza Namazi, Ismaeil Haririan, et al

International Journal of Nanomedicine 2010, 5:455-461

Published Date: 29 June 2010

Validation of the cell cycle G2 delay assay in assessing ionizing radiation sensitivity and breast cancer risk

Jeff W Hill, Kristina Tansavatdi, Kristin L Lockett, Glenn O Allen, et al.

Cancer Management and Research 2009, 1:39-48

Published Date: 30 April 2009

Role of bendamustine in the treatment of chronic lymphocytic leukemia

Saad Jamshed, Bruce D Cheson

OncoTargets and Therapy 2009, 2:43-49

Published Date: 12 March 2009

Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease

Felix C Ringshausen, Ai-Yui M Tan, Tobias Allander, Irmgard Borg, Umut Arinir, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:111-117

Published Date: 4 February 2009

Vascular dementia: Pharmacological treatment approaches and perspectives

Andrius Baskys, Anthony C Hou

Clinical Interventions in Aging 2007, 2:327-335

Published Date: 15 October 2007